Sonoma Pharmaceuticals, Inc. Uncategorized Contracts & Agreements

102 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Offer letter to John Dal Poggetto dated February 7, 2024
Sonoma Pharmaceuticals, Inc.
2024
Offer letter to Jerome Dvonch dated February 7, 2024
Sonoma Pharmaceuticals, Inc.
2024
Offer letter to John Dal Poggetto dated July 11, 2023
Sonoma Pharmaceuticals, Inc.
2023
Amendment to At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc., dated February 24, 2023
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2023
At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc., dated December 23, 2022
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
NY
2022
Offer letter to Chad White dated September 8, 2022
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2022
At-The-Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated July 30, 2021
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
NY
2021
Offer letter J. Dvonch dated August 10, 2020
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2020
Licensing Agreement between Sonoma Pharmaceuticals, Inc. and Microsafe Group, effective July 27, 2020
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
DE
2020
Master Vendor Agreement by and between Sonoma Pharmaceuticals, Inc. and PetSmart Home Office, Inc., dated November 21, 2016
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
AZ
2017
BACKGROUND
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2016
BACKGROUND
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
CA
2016
SECURITIESPURCHASE AGREEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
NY
2014
Oculus Innovative Sciences, Inc. 1129 North McDowell Boulevard Petaluma, CA 94954
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2013
ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIALMULTI-TENANT LEASE-GROSS BY AND BETWEEN KCMKCPROPERTIES, LLP, AS LESSOR, AND OCULUS INC. A DELAWARE CORPORATION, AS LESSEE FOR THE...
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2012
Venture Lending & Leasing VI, Inc. 104 La Mesa Dr., Suite 102 Portola Valley, CA 94028 October 30, 2012
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2012
Venture Lending & Leasing V, Inc. 104 La Mesa Dr., Suite 102 Portola Valley, CA 94028 October 30, 2012
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2012
STOCKPURCHASE AGREEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
CA
2012
SUPPLEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
CA
2011
PRODUCTOPTION AGREEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
NY
2011
EXCLUSIVECO-PROMOTION AGREEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
NY
2011
DISTRIBUTIONAGREEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2011
PURCHASEAGREEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
CA
2010
SECURITIESPURCHASE AGREEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
NY
2010
Exhibit10.1 CONTINUOUSOFFERING PROGRAM AGREEMENT
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
NY
2010
We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
CA
2009
We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
DE
2009
We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
CA
2009
We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2009
Entry Into a Material Definitive Agreement
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
2009
Entry Into a Material Definitive Agreement
Sonoma Pharmaceuticals, Inc.
Pharmaceuticals
CA
2009
Current assets
Sonoma Pharmaceuticals, Inc.
2008
Complete a meeting with FDA regarding our Phase II results and pivotal trial protocols
Sonoma Pharmaceuticals, Inc.
2008
Complete a meeting with FDA regarding our Phase II results and pivotal trial protocols
Sonoma Pharmaceuticals, Inc.
2008
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
Sonoma Pharmaceuticals, Inc.
2008
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
Sonoma Pharmaceuticals, Inc.
2008
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
Sonoma Pharmaceuticals, Inc.
2008
Initiate and complete Phase II trial for use of Microcyn in the treatment of infections in mildly infected diabetic foot ulcers
Sonoma Pharmaceuticals, Inc.
2007
Initiate and complete Phase II trial for use of Microcyn in the treatment of infections in mildly infected diabetic foot ulcers
Sonoma Pharmaceuticals, Inc.
2007
Initiate and complete Phase II trial for use of Microcyn in the treatment of infections in mildly infected diabetic foot ulcers
Sonoma Pharmaceuticals, Inc.
2007